What is Stifel Canada’s Estimate for TSE:HLS Q1 Earnings?

HLS Therapeutics Inc. (TSE:HLS) – Investment analysts at Stifel Canada issued their Q1 2025 EPS estimates for HLS Therapeutics in a research note issued to investors on Tuesday, March 25th. Stifel Canada analyst J. Keywood forecasts that the company will earn ($0.16) per share for the quarter. The consensus estimate for HLS Therapeutics’ current full-year earnings is ($0.12) per share. Stifel Canada also issued estimates for HLS Therapeutics’ Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.43) EPS.

Separately, Stifel Nicolaus raised their price objective on HLS Therapeutics from C$3.50 to C$4.00 and gave the company a “hold” rating in a research note on Wednesday.

HLS Therapeutics Stock Performance

HLS opened at C$4.52 on Thursday. The company has a market cap of C$100.56 million, a PE ratio of -4.53 and a beta of 1.07. The stock has a 50-day moving average of C$4.18 and a 200-day moving average of C$3.80. HLS Therapeutics has a 52-week low of C$3.00 and a 52-week high of C$5.48. The company has a debt-to-equity ratio of 86.50, a quick ratio of 1.01 and a current ratio of 1.56.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.